KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Short term Debt (2019 - 2025)

Vir Biotechnology's Short term Debt history spans 5 years, with the latest figure at $17.5 million for Q1 2025.

  • For Q1 2025, Short term Debt changed N/A year-over-year to $17.5 million; the TTM value through Mar 2025 reached $17.5 million, changed N/A, while the annual FY2024 figure was $16.1 million, N/A changed from the prior year.
  • Short term Debt for Q1 2025 was $17.5 million at Vir Biotechnology, up from $16.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $68.5 million in Q3 2021 and bottomed at $16.1 million in Q4 2024.
  • The 3-year median for Short term Debt is $24.4 million (2021), against an average of $30.5 million.
  • The largest YoY upside for Short term Debt was 457.45% in 2021 against a maximum downside of 128.04% in 2021.
  • A 3-year view of Short term Debt shows it stood at $68.5 million in 2021, then plummeted by 76.55% to $16.1 million in 2024, then increased by 8.97% to $17.5 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Short term Debt are $17.5 million (Q1 2025), $16.1 million (Q4 2024), and $68.5 million (Q3 2021).